Ronald L. Goode, Advisory Board, Biotechnology and Pharmaceuticals,

has decades of global experience as a scientist and senior executive in the biotechnology and pharmaceuticals industry. Dr. Goode taps his considerable knowledge and expertise on behalf of Kinsella Group and our clients, advising on the formation of international alliances, developing joint ventures, and other key corporate transactions in the field of healthcare products and services.

Dr. Goode has served in key leadership roles in a number of well-known and cutting-edge pharmaceutical companies. He has held senior management positions at Pfizer Pharmaceuticals, including Vice President of Clinical Research and Scientific Affairs, and Director of Marketing Research, among other responsibilities. At G.D. Searle & Co., he served as Senior Vice President of Commercial Development, President of Asia/Pacific World Area, and President of Searle International.

For these companies, Dr. Goode has supervised clinical development programs that led to the filing of over a dozen New Drug Approval applications, including Pfizer's Procardia XL® and Searle's Ambien®. During this period, he also developed an extensive record of successful business development, having been responsible for many of Searle's acquisitions, including DayPro®, which became Searle's largest-selling drug.

Dr. Goode has served as President and Chief Executive Officer of two public companies, Unimed Pharmaceuticals, Inc. and eXegenics Inc. He also served as a Director of Unimed until the company was sold to Solvay Et Cie, the Belgium-based conglomerate, and on the Board of Directors of eXegenics, the final year of which he also served as Chairman.

In addition to these leadership positions, Dr. Goode served as a Director for a number of other public companies, including Vitro Diagnostics, Inc. (a Nevada-based company), and Hokuriku Seiyaku (in which he was the only non-Japanese Director for this publicly held Japanese pharmaceutical company). He presently serves on the Board of Directors of Genitope (Nasdaq: GTOP) and on the Advisory Boards of ART Recherchés et Technologies Avancées Inc. (Toronto: ARI) and Greystone Pharmaceutical Group.

Recently, he formed his own consulting company (dba "The Goode Group") with the mission of creating "links" between pharmaceutical companies to help them devise alliances, form joint ventures and implement various transactions. Under Sarbanes-Oxley, Dr. Goode is also qualified to serve as an "Audit Committee Financial Expert."

Throughout his service in these various roles, Dr. Goode has developed broad expertise in global business operations, including full P&L responsibility, product development, launch and marketing, business development, mergers and acquisitions, financial operations and financing. He also has significant experience in managing class action lawsuits, proxy fights, D&O insurance issues, NASDAQ listing issues, and the like.

In 2000, Dr. Goode and his wife, Sheila, spent a sabbatical with his charity of choice, Mercy Ships International. Among the non-profit Boards of Directors/Trustees on which he serves are those of Mercy Ships and Thunderbird, The Garvin Graduate School of International Management. Dr. Goode received his Ph.D. in Microbial Genetics from the University of Georgia.